This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable
The company doses first patient in US study of Deraphan, as Dolby Ventures joins €53M Series B to support neuropsychiatric innovation
Children 5 through 11 years of age are now authorized to receive a booster dose at least five months after the second dose of the two-dose primary series
A separate global Phase 3 study of S-217622 is underway aiming to recruit participants globally to support regulatory filings this year
All the recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval.
Expanded EUA includes both treatment of patients with Covid-19 and post-exposure prophylaxis (PEP) in high-risk pediatric and infant patients
The trial will be conducted across 10 sites in India
Subscribe To Our Newsletter & Stay Updated
